Lyra Therapeutics, Inc.

As of August 12, 2025, Lyra Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify" due to its high Price to Book Value of 8.31, negative earnings ratios, and a significantly low Return on Equity of -1111.31%, alongside poor stock performance compared to the S&P 500.

As of August 9, 2022, Lyra Therapeutics, Inc. is considered overvalued and classified as risky, with concerning financial ratios including a price-to-book value of 8.31 and an ROE of -1111.31%, especially when compared to peers like ATAI Life Sciences and Eagle Pharmaceuticals.

As of June 17, 2025, the trend is mildly bullish due to positive weekly and monthly MACD and RSI readings, though daily moving averages present some bearish caution, resulting in a cautiously optimistic outlook.

As of March 2022, the management team of Lyra Therapeutics, Inc. includes Dr. Maria Palasis as President, CEO, and Director, and Dr. Nancy Snyderman as a member of the Board of Directors.

Lyra Therapeutics, Inc. is a clinical-stage company developing localized drug delivery solutions for ENT diseases. As of March 2025, it has a market cap of $13.62 million, with net sales of $0 and a net loss of $9 million.

As of Jun 18, Lyra Therapeutics, Inc. has a market capitalization of 13.62 million, with net sales of 1.19 million and a net profit of -79.53 million over the last four quarters. The company reported shareholder's funds of 11.59 million and total assets of 66.35 million as of Dec 24.